GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells

Tivantinib has been described as a potent and highly selective inhibitor of the receptor tyrosine kinase c-MET and is currently in advanced clinical development for several cancers including non-small cell lung cancer (NSCLC). However, recent studies suggest that tivantinib’s anticancer properties a...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Remsing Rix, Lily L., Kuenzi, Brent M., Luo, Yunting, Remily-Wood, Elizabeth, Kinose, Fumi, Wright, Gabriela, Li, Jiannong, Koomen, John M., Haura, Eric B., Lawrence, Harshani R., Rix, Uwe
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3944088/
https://ncbi.nlm.nih.gov/pubmed/24215125
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/cb400660a
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki